Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal-Making Darling Among Latest To Retract China NDAs

This article was originally published in PharmAsia News

Executive Summary

Very few people doubt about what China FDA can do to reduce its notorious drug approval backlog, the agency's actual moves and impact to the industry, however, is shocking to many. Meanwhile, a rigorous clinical data review has been expanded to Beijing and Shanghai with local FDA involved.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC088580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel